**Table, Supplemental Digital Content 4:**

Possible predictors of clinical remission at week 14

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | OR | 95% CI | P value |
| Disease type (CD) | 0.85 | 0.12-6 | 0.87 |
| Gender (female) | 0.73 | 0.17-3.1 | 0.66 |
| Extra-intestinal manifestations | 1.5 | 0.36-6 | 0.58 |
| Concomitant immunomodulator use | 2 | 0.4-10 | **0.4** |
| Parameter | Medians | IQRs | P value |
| Age at induction (years) | 15 versus 12.5 | 11-17 versus 12-14 | 0.20 |
| BMI at induction (kg) | 18.7 versus 17.3 | 15.5-20.8 versus 15.4-18.5 | 0.46 |
| Albumin at induction (g/dL) | 3.9 versus 3.8 | 3.7-4.3 versus 3.2-3.9 | 0.10 |
| Week 2 IFX-TL (µg/ml) | 12.8 versus 7.6 | 9.7-16.2 versus 2.1-12.9 | **0.02** |
| Week 6 IFX-TL (µg/ml) | 8.4 versus 5.5 | 6.9-17.0 versus 0.27-12.3 | **0.04** |
| Week 2 ATI (µg/ml) | 1.2 versus 2.0 | 0.45-2.0 versus 1.6-3.5 | **0.04** |
| Week 6 ATI (µg/ml) | 0.9 versus 1.6 | 0.6-1.9 versus 0.8-8.6 | **0.11** |

CD – Crohn’s disease, IFX-TL- Infliximab trough level, ATI – Antibodies to Infliximab.